GLP's
Tirzepatide
30 mg
Dual incretin agonist (GIP / GLP-1)
$85
Research overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist. FDA-approved products containing tirzepatide have specific clinical indications, while research-grade material should be discussed only in lawful research context and never as an informal treatment substitute.
Potential research areas
- Incretin signaling
- Glucose regulation pathways
- Metabolic syndrome research
- Appetite and satiety models
- Form
- Lyophilized Powder
- Category
- Research Peptide
- Use
- Research Only